BioCryst Pharmaceuticals (BCRX) Earnings Date, Estimates & Call Transcripts $7.06 -0.29 (-3.95%) (As of 11/5/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BioCryst Pharmaceuticals Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 24EstimatedActual EPS (Nov. 4) -$0.07 Consensus EPS (Nov. 4) -$0.07 BioCryst Pharmaceuticals issued Q3 2024 earnings on November 4, 2024, reporting an EPS of -$0.07, which met analysts' consensus estimates of -$0.07. Quarterly revenue rose 35.1% year-over-year to $117.10 million, above the consensus estimate of $113.99 million. With a trailing EPS of -$0.61, BioCryst Pharmaceuticals' earnings are expected to grow next year, from ($0.37) to ($0.19) per share. Conference Call AudioEarnings Press ReleaseEarnings Slide DeckBCRX Upcoming EarningsBioCryst Pharmaceuticals' next earnings date is estimated for Monday, February 24, 2025, based off prior year's reporting schedules. Get BioCryst Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBCRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BCRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade BioCryst Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.19-$0.19-$0.19Q2 20241-$0.14-$0.14-$0.14Q3 20241-$0.03-$0.03-$0.03Q4 20241-$0.03-$0.03-$0.03FY 20244($0.39)($0.39)($0.39) BioCryst Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/24/2025(Estimated)------- 11/4/2024Q3 2024-$0.07-$0.07--$0.07$113.99M$117.10M 8/5/2024Q2 2024-$0.17-$0.06+$0.11-$0.06$98.30M$109.30M 5/6/2024Q1 2024-$0.23-$0.17+$0.06-$0.17$85.62M$92.80M 2/26/2024Q4 2023-$0.24-$0.28 -$0.04-$0.25$89.19M$93.40M 11/2/2023Q3 2023-$0.25-$0.19+$0.06-$0.19$86.54M$86.74M 8/3/2023Q2 2023-$0.25-$0.24+$0.01-$0.08$81.42M$81.01M Get the Latest News and Ratings for BCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/3/2023Q1 2023-$0.30-$0.28+$0.02-$0.28$71.44M$68.80M 2/21/2023Q4 2022-$0.19-$0.38 -$0.19-$0.38$74.18M$79.50M BioCryst Pharmaceuticals Earnings - Frequently Asked Questions When is BioCryst Pharmaceuticals's earnings date? BioCryst Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based off last year's report dates. Learn more on BCRX's earnings history. Did BioCryst Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) reported ($0.07) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.07). Learn more on analysts' earnings estimate vs. BCRX's actual earnings. How can I listen to BioCryst Pharmaceuticals's earnings conference call? The conference call for BioCryst Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How much revenue does BioCryst Pharmaceuticals generate each year? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded annual revenue of $382.24 million. How much profit does BioCryst Pharmaceuticals generate each year? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded net income of -$226.54 million. BCRX has generated -$0.61 earnings per share over the last four quarters. What is BioCryst Pharmaceuticals's EPS forecast for next year? BioCryst Pharmaceuticals's earnings are expected to grow from ($0.37) per share to ($0.19) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies TSHA Earnings Date ADAP Earnings Date VXRT Earnings Date PASG Earnings Date ALGS Earnings Date KRYS Earnings Date MDGL Earnings Date IONS Earnings Date ALKS Earnings Date FOLD Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade This page (NASDAQ:BCRX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCRX Stock Alerts